Azul: Add This Stock To Your Watchlist
Summary
- Following the stock's 55% drop in only six weeks, Azul continues to report very solid operational metrics.
- Domestic flights have not been impacted by the COVID-19 spread, but traffic growth could decelerate later in the winter season.
- Is now the right time to buy airline stocks? Probably not. But I believe AZUL should eventually reclaim previous highs.
- Looking for a helping hand in the market? Members of Storm-Resistant Growth get exclusive ideas and guidance to navigate any climate. Get started today »
Given the current market rout that has been particularly damaging to companies in the travel and leisure industry, this may be the worst time to discuss airline stocks. But following Azul's (NYSE:AZUL) February traffic update, I find myself compelled to talk about this particular name, which has been down a mind-boggling 55% in less than six weeks.
Azul reported traffic numbers that impressed once again, despite growth in RPK (revenue passenger kilometers) and ASK (available seat kilometer) having decelerated since 4Q19. Occupancy improved minimally YOY in February, a feat that I don't believe any airline in the US has been able to pull off in the most recent month.
Credit: Flickr
Traffic remains robust
The COVID-19 spread had already been a hot topic of conversation since January 2019, but the negative business implications did not start to surface until the second week of February. Still, possibly due to the fact that (1) the disease did not spread to Brazil until February 25 and (2) roughly 75% of Azul's traffic is domestic, the Barueri-based company does not seem to have suffered the consequences of the virus's global proliferation.
The graphs below depict RPK and ASK trends at the total company level since the early 2017 IPO. Notice how growth in both cases has been decelerating since October 2019 still to an impressive 25% YOY in February.
However, the downward trend started to form well ahead of any breaking news on the COVID-19 and seems to be better explained by a natural correction that followed the initial (positive) impact of Azul's Rio-São Paulo route debut, in late August 2019. In fact, only the domestic segment has been experiencing traffic growth declines, while the international division continues to recover steadily from April 2019 lows - for now, at least.
Source: DM Martins Research, using data from company's traffic reports
It is likely that Azul's operational performance will eventually suffer a bit over the next few months. Flights from Brazil to Italy that make a connection in Portugal have already been impacted by the virus spread, as Azul has been offering international customers a full refund on this particular route.
However, I don't expect traffic growth to fall off a cliff. My checks in Brazil indicate that other of Azul's international routes have not yet been altered due to the health crisis, and that domestic flights continue to operate as scheduled. Because bookings tend to precede trips by at least a month or more, any potential impact from a falling Brazilian Real or from fears of an imminent global recession would likely not manifest itself until the southern hemisphere's late fall and early winter weeks.
Don't fire quite yet
Azul's golden days of 30%-plus traffic and capacity growth have certainly been left a few months behind. However, it does not look like the company has been or will be suffering much from the dreaded COVID-19 spread - at least not to the extent that the stock's 55% drop of the past month and a half seems to suggest, or unless the global health crisis escalates substantially.
Data by YCharts
The same factors that made me an AZUL bull a couple of years ago continue to be in place: (1) dominance in the highly profitable small-to-mid size market in Brazil, (2) the fleet upgrade that has been leading to more fuel efficiency and lower CASM-ex (i.e. per unit cost ex-fuel), and (3) the company's fast-growing loyalty program. It helps that the stock is now selling at a next-year earnings multiple of 8.3x that I find overly discounted.
But I can't ignore the fact that equity markets are still in the middle of the sharpest and fastest correction off an all-time peak in history. Things could get a lot uglier before they get better. In addition, it is still a bit premature to make a well-informed call on the long-term economic impact of the COVID-19 scare.
Therefore, I believe AZUL deserves a spot in the "stocks to buy on weakness" watchlist. In the end, and given enough time (maybe even a few years), AZUL should reclaim and eventually surpass its all-time highs of $44/ADS. But trying to time an entry when stocks remain stuck in the eye of the tornado can be a risky proposition. I would rather wait for signs of a broad market recovery before pulling the trigger on a volatile, pro-cyclical name like AZUL - even if I miss out on the first ten to fifteen percentage points of the upswing.
I do not yet own AZUL because I have been focused on creating superior risk-adjusted returns in the long run using a different strategy. To dig deeper into how I have built a risk-diversified portfolio designed and back-tested to generate market-like returns with lower risk, join my Storm-Resistant Growth group. Take advantage of the 14-day free trial, read all the content written to date and get immediate access to the community.
This article was written by
Daniel Martins is a Napa, California-based analyst and founder of independent research firm DM Martins Research. The firm's work is centered around building more efficient, easily replicable portfolios that are properly risk-balanced for growth with less downside risk.
- - -
Daniel is the founder and portfolio manager at DM Martins Capital Management LLC. He is a former equity research professional at FBR Capital Markets and Telsey Advisory in New York City and finance analyst at macro hedge fund Bridgewater Associates, where he developed most of his investment management skills earlier in his career. Daniel is also an equity research instructor for Wall Street Prep.
He holds an MBA in Financial Instruments and Markets from New York University's Stern School of Business.
- - -
On Seeking Alpha, DM Martins Research partners with EPB Macro Research, and has collaborated with Risk Research, Inc.
DM Martins Research also manages a small team of writers and editors who publish content on several TheStreet.com channels, including Apple Maven (thestreet.com/apple) and Wall Street Memes (thestreet.com/memestocks).
Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Recommended For You
Comments (5)



Can you help me on the debt. Actual long term bonds o/s
